Efficacy of Two Enzyme Cocktails in Healthy Adults

NCT ID: NCT06710392

Last Updated: 2024-11-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-15

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to determine the safety and efficacy of two enzyme cocktails in healthy adults with mild to moderate gastrointestinal discomfort. The main question aims to answer whether a 4-week administration of an enzyme cocktail can improve how the participant feels about their gut health. This is done by completing a weekly questionnaire, and the results are compared between the 4 weeks the participants are on a placebo and the 4 weeks the participants are on the enzyme cocktail. Participants will also provide a stool sample at the start and end of each treatment. Stool samples will collected and stored in case further microbiome analysis is warranted.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Digestive Gastrointestinal Health

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

enzyme enzyme cocktail healthy adults nutraceutical

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Digestive Enzyme Cocktail A

Arm receiving investigational product A

Group Type EXPERIMENTAL

Enzyme Cocktail A

Intervention Type DIETARY_SUPPLEMENT

Enzyme cocktail A in the form of a capsule with a daily dose of 275mg taken 3 times a day for 4 weeks.

Digestive Enzyme Cocktail B

Arm receiving investigational product B

Group Type EXPERIMENTAL

Enzyme Cocktail B

Intervention Type DIETARY_SUPPLEMENT

Enzyme cocktail B in the form of a capsule with a daily dose of 50mg taken 3 times a day for 4 weeks.

Placebo A

Arm receiving placebo A

Group Type PLACEBO_COMPARATOR

Placebo A

Intervention Type DIETARY_SUPPLEMENT

Placebo A matching investigational product A given 3 times a day for 4 weeks.

Placebo B

Arm receiving Placebo B

Group Type PLACEBO_COMPARATOR

Placebo B

Intervention Type DIETARY_SUPPLEMENT

Placebo B matching investigational product B given 3 times a day for 4 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enzyme Cocktail A

Enzyme cocktail A in the form of a capsule with a daily dose of 275mg taken 3 times a day for 4 weeks.

Intervention Type DIETARY_SUPPLEMENT

Enzyme Cocktail B

Enzyme cocktail B in the form of a capsule with a daily dose of 50mg taken 3 times a day for 4 weeks.

Intervention Type DIETARY_SUPPLEMENT

Placebo A

Placebo A matching investigational product A given 3 times a day for 4 weeks.

Intervention Type DIETARY_SUPPLEMENT

Placebo B

Placebo B matching investigational product B given 3 times a day for 4 weeks.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Presence of a serious congenital anomaly or chronic medical condition that would contraindicate participation, including history of major gastrointestinal surgery, chronic gastrointestinal illness, abnormal intestinal anatomy or significant abdominal disorder
* Having taken oral antibiotics in the previous 3-months or if they start antibiotics during the study
* Currently or having taken a prebiotic, probiotic, or digestive enzyme supplement in the previous 3-months
* Currently consuming 1 or more servings of fermented foods or yogurt on a daily basis
* Doctor diagnosed chronic disease (i.e. Diabetes, Cardiovascular, etc.)
* Doctor diagnosed immunodeficiency
* Current use of doctor prescribed immunosuppressive agents (corticosteroids, methotrexate, etc.)
* Pregnancy, 6 months postpartum period, or current breastfeeding
* Women of childbearing age planning pregnancy during the course of the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of North Texas, Denton, TX

OTHER

Sponsor Role collaborator

The Archer-Daniels-Midland Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University of North Texas

Denton, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dr. McFarlin

Role: CONTACT

Phone: 940-565-2232

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CTB2022TN225D

Identifier Type: -

Identifier Source: org_study_id